/HOWL
HOWL Stock - Werewolf Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.69+6.22%
+$0.04 (+6.22%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.9
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.90
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+45.6%upside
Target: $1.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HOWL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.68 – $0.69
TARGET (TP)$1.00
STOP LOSS$0.63
RISK/REWARD1:5.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.74
52W High$2.38
52W Low$0.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.89M | $19.94M | $16.40M | N/A | N/A |
| Gross Profit | $71,000 | $18.18M | $13.89M | N/A | $-777,000 |
| Gross Margin | 3.8% | 91.2% | 84.7% | N/A | N/A |
| Operating Income | $-73,594,000 | $-40,503,000 | $-56,056,000 | $-50,087,000 | $-22,404,000 |
| Net Income | $-70,515,000 | $-37,368,000 | $-53,810,000 | $-49,983,000 | $-14,939,000 |
| Net Margin | -3740.8% | -187.4% | -328.1% | N/A | N/A |
| EPS | $-1.63 | $-1.05 | $-1.86 | $-10.94 | $-0.98 |
Company Overview
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$9
Average Target
↑ 1137.6% Upside
Now
$1
Low
$9
Average
$12
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 19th 2025 | Wedbush | Downgrade | Neutral | $1 |
| April 3rd 2024 | JMP Securities | Initiation | Mkt Outperform | $12 |
| August 24th 2023 | Wedbush | Initiation | Outperform | $9 |
| June 6th 2023 | Jefferies | Resumed | Buy | $12← $11 |
Earnings History & Surprises
HOWLBeat Rate
58%
Last 19 quarters
Avg Surprise
-1009.1%
EPS vs Estimate
Beats / Misses
11/8
Last 12 quarters
Latest EPS
$-0.36
Q4 2025
EPS Surprise History
Q1 24
+23.3%
$-0.33vs$-0.43
Q2 24
-11.4%
$-0.39vs$-0.35
Q3 24
-13.2%
$-0.43vs$-0.38
Q4 24
+7.3%
$-0.38vs$-0.41
Q1 25
-7.0%
$-0.46vs$-0.43
Q2 25
+9.1%
$-0.40vs$-0.44
Q3 25
+20.0%
$-0.40vs$-0.50
Q4 25
+7.7%
$-0.36vs$-0.39
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 10, 2026 | $-0.40 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.39 | $-0.36 | +7.7% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.50 | $-0.40 | +20.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.44 | $-0.40 | +9.1% | ✓ BEAT |
Q1 2025 | Mar 11, 2025 | $-0.43 | $-0.46 | -7.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.41 | $-0.38 | +7.3% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.38 | $-0.43 | -13.2% | ✗ MISS |
Q2 2024 | May 3, 2024 | $-0.35 | $-0.39 | -11.4% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.43 | $-0.33 | +23.3% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.27 | $-0.23 | +14.8% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.41 | $-0.14 | +65.9% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.49 | $-0.34 | +30.6% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.59 | $-0.39 | +33.9% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.60 | $-0.40 | +33.3% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.30 | $-0.53 | -76.7% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.60 | $-0.56 | +6.7% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $-0.56 | $-0.66 | -17.9% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.45 | $-0.51 | -13.3% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.28 | $-3.82 | -1264.3% | ✗ MISS |
Q2 2021 | Jun 10, 2021 | $-0.46 | $-83.36 | -18021.7% | ✗ MISS |
Latest News
HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $4
➖ NeutralBenzinga•Dec 19, 2025, 12:44 PM
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $7
➖ NeutralBenzinga•Nov 18, 2025, 05:59 PM
Werewolf Therapeutics Releases Preclinical Data Demonstrating Its Inducer T Cell Engager Platform And Indukine Molecules Show Potent Antitumor Activity With Reduced Systemic Toxicity
📈 PositiveBenzinga•Nov 7, 2025, 02:05 PM
Werewolf Therapeutics Q3 EPS $(0.36) Beats $(0.39) Estimate
📈 PositiveBenzinga•Nov 4, 2025, 12:06 PM
Reported Earlier: Werewolf Therapeutics Receives Fast Track Designation For The Use Of WTX-124 For The Potential Treatment Of Patients With Locally Advanced Or Metastatic Cutaneous Melanoma After Standard Of Care Immunotherapy
📈 PositiveBenzinga•Oct 8, 2025, 02:22 PM
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $8
➖ NeutralBenzinga•Aug 25, 2025, 04:55 PM
JMP Securities Maintains Market Outperform on Werewolf Therapeutics, Lowers Price Target to $3
➖ NeutralBenzinga•Aug 21, 2025, 01:11 PM
Frequently Asked Questions about HOWL
What is HOWL's current stock price?
Werewolf Therapeutics, Inc. (HOWL) is currently trading at $0.69 per share. The stock has moved +6.22% today.
What is the analyst price target for HOWL?
The average analyst price target for HOWL is $1.00, based on 1 analyst.
What sector is Werewolf Therapeutics, Inc. in?
Werewolf Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is HOWL's market cap?
Werewolf Therapeutics, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does HOWL pay dividends?
No, Werewolf Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACET
Adicet Bio, Inc.
$0.49
Mkt Cap: $0.0B
CUE
Cue Biopharma, Inc.
$0.27
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
IOBT
IO Biotech, Inc.
$0.66
Mkt Cap: $0.0B
LITS
Lite Strategy, Inc.
$1.43
Mkt Cap: $0.1B
NRXP
NRx Pharmaceuticals, Inc.
$2.37
Mkt Cap: $0.0B
OSTX
OS Therapies Incorporated
$1.54
Mkt Cap: $0.1B
OTLK
Outlook Therapeutics, Inc.
$2.01
Mkt Cap: $0.1B
SPRB
Spruce Biosciences, Inc.
$78.74
Mkt Cap: $0.0B
Explore stocks similar to HOWL for comparison